Join Telix at EANM 2022 to discover how nuclear medicine is shifting perspectives in Genitourinary Oncology

7 October 2022

Telix is looking forward to hosting another symposium, this time at EANM 2022. We have an exciting line-up of key speakers who will each present their own shifting perspectives before opening the discussion up to the floor. Nuclear medicine is a fast-moving field, so don’t miss out on the opportunity to enhance your knowledge and discover new, game-changing viewpoints on Genitourinary Oncology.

Barcelona, Spain

Sunday 16th October 2022 from 13:15 – 14:45

Hall 211, CCIB (Centre de Convencions Internacional de Barcelona)

  • Prof Wolfgang Fendler, Vice Chair at the Clinic for Nuclear Medicine, Essen University Hospital, Essen, Germany
    • PSMA-ligand PET imaging: current status and impact on patient management (20 min)
  • Prof Jochen Walz, Head of the Department of Urology at the Institut Paoli-Calmettes Cancer Centre, Marseille, France
    • Interventional nuclear medicine: focus on radioguided surgery in urology cancers (20 min)
  • Dr Stijn Muselaers, Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
    • Redefining the management of renal cancer patients (20 min)
  • Prof Zéna Wimana, Radiopharmacy Manager, Department of Nuclear Medicine, Institut Jules Bordet, Brussels, Belgium
    • Establishing radio ligand imaging and therapy in hospital practice (20 min)

Speaker biographies

Professor Wolfgang Fendler (Chair and Speaker)
Wolfgang Fendler obtained his medical degree from the Ludwig Maximilian University of Munich. He is a Senior Consultant and Vice Chair at the Clinic for Nuclear Medicine, Essen University Hospital, Essen, Germany, where he also heads up the research group “Translational Oncology”. In Jan 2021 he joined the medical faculty at University of Duisburg-Essen as an außerplanmäßiger Professor. His research focuses primarily on the assessment of theranostic radioligands and radionuclides, i.e., molecules designed to deliver radioactive payloads into tumor lesions. Wolfgang has published several studies aimed at achieving a better understanding of the accuracy of PSMA PET as well as its impact on management. His other published studies look at the targeting of fibroblast activation protein with radioligands for diagnostic and therapeutic in the tumour microenvironment. He is on the editorial board of the Journal of Nuclear Medicine and has been a reviewer for European Urology, European Clinical Cancer Research, BMC Cancer, PLOS ONE, amongst others. He is a member of the German Society for Nuclear Medicine, the European Association of Nuclear Medicine, and the European Association of Urology

Prof Jochen Waltz (Speaker)
Jochen Christoph Walz is a Professor in Urology and Head of the Department of Urology at the Institut Paoli-Calmettes Cancer Centre in Marseille, France. He attended the Medical School of the University of Mainz, Germany and, following his dissertation, he completed his residency in Urology at the Universities of Marseille, France and Hamburg, Germany. He has been a board-certified urologist since 2005. He became a research fellow at the Cancer Prognostics and Health Outcomes Unit at the University of Montreal, Canada in 2006/7 and received his “Habilitation” in 2008 in Urology at the University of Hamburg, Germany. From 2009 to 2017 he was Chairman of the EAU Section of Urological Imaging. He specializes in uro-oncology and urological imaging. His main areas of research are imaging in urology, prostate cancer (imaging and diagnosis), prediction tools, life expectancy, surgical treatment, and minimal invasive surgery. Dr. Walz is also Co-Editor-in-Chief of European Urology Open Science.

Doctor Stijn Muselaers (Speaker)
Stijn Muselaers completed medical school and his residency in Urology at the Radboud University in Nijmegen, the Netherlands. In 2015, he successfully defended his PhD thesis entitled ‘Targeting renal cell with radiolabelled antibodies’. Nowadays, he works as an oncological urologist at the Radboud University Medical Center in Nijmegen with a focus on renal and prostate cancer.

Prof. Zéna Wimana (Speaker)

Prof. Zéna Wimana obtained her PhD in Biomedical and Pharmaceutical sciences from the Université Libre de Bruxelles (ULB) Belgium, where she currently teaches radiopharmacy and leads the Radiopharmaceutical Research Unit of the LOCE Lab at the faculty of medicine. In parallel, she became the manager of the radiopharmacy department at the Jules Bordet Institute and contributed to the introduction of several radiopharmaceuticals in the clinic as premier in Belgium (eg. 89Zr-Trastuzumab, 177Lu-DOTATATE, 68Ga-PSMA). She is also a board member in different scientific and professional associations, including the Belgian Association of Radiopharmaceutical Research (BARR) under the umbrella of the Belgian nuclear medicine society (BelNuc)

What a line up – we can’t wait for you to join us in Barcelona!